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progression to a different chemotherapeutic antiblastic regimen. The 
treatment with Pemetrexed started after registration of Pemetrexed in 
Italy (May 2005) as an option for NSCLC after failure of the ﬁrst line 
regimen. All patients were required to take a premedication with folic 
acid and vitamin B12 supplements as well as corticosteroids.
Results: Data were collected from 160 patients, treated between May 
2005 and October 2006. The analysis was performed on the data up 
to January 31st 2007. All patients were affected by NSCLC, the most 
represented histology was adeno- (50.4%) and squamous cell carci-
noma (22.2%); mostly males, 117 ( 73.1%) versus 43 females (26.5%), 
and smokers (91.2%). 147 patients (91.9%) were affected by IV and 
13 (8.1%) by IIIB disease. The median age was 63.2 years (41-82); 41 
patients out of 160 (25.6%) were elderly,≥ 70 years. PS was 0 in 15% 
of the patients, 1 in 65.6%, 2 in 9%. 
Most of the patients were previously treated with a platinum-based che-
motherapy, except 6 (3.7%). The total number of cycles of Pemetrexed 
was 536, the median number of cycles of 3,3 per patient; 60 out of 
160, (37.5% ) received 3 cycles of Pemetrexed, 31 completed 6 cycles 
(19.4%); a few of them received more than 6 cycles (3 and 1 patient 
had 8 and 9 cycles respectively). About response, 17 patients (11.2%) 
showed a complete or partial response (CR and PR), 82 (51.2%) a pro-
gressive (PD) and 44 (27.5%) a stable disease (SD). The clinical beneﬁt 
(PR+CR+SD) was gained in 38.1% of patients.
4 patients out of 160 experienced a delay in chemo-administration: 
two patients due to urinary infection, and 2 patients due to pre-existent 
morbidities ( Crohn disease and ischaemic myocardial failure). Hema-
tological toxicities were mild, anemia G1 and G2 in 21 (13%) and 3 
patients (1.9%) respectively, leucopenia G3 in 3 (1.9%), thrombocy-
topenia G3 in 1 patient (0.6%); non-hematological toxicities consisted 
in fatigue (G1 in 11 and G2 in 9 patients, 6.9 and 5.6 % respectively), 
neurologic toxicitiy G2 in 3 patients (1.9%), stomatitis G2 in 2 patients, 
renal toxicity G2 in 1 patient and nausea G2 in 6 patients (3.7%).
The overall survival rate was assessed by Kaplan and Meier methods 
on 154 patients. The median survival, by the beginning of treatment 
with Pemetrexed, was 7.8 months.
Conclusion: Treatment of NSCLC with Pemetrexed in the second-line 
setting is feasible, active and tolerable and could represent an interest-
ing option for elderly or poor PS patients.
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Background: Survival of lung cancer is dismal particularly in de-
veloping countries. Chemotherapy may be one option in most cases. 
Cisplatin-based chemotherapy provides survival advantage, improved 
symptoms and quality of life (BMJ 1995, Rinaldi, M et al 2006) even 
in developing countries (Shajeem et al 2003). A number of new active 
drugs have been used. But cost factor is an important and perhaps the 
only constraint. We tried a relatively cheaper drug combination of 
irinotecan and cisplatin in patients of lung cancer (NSCLC and SCLC). 
Material and Method: Physical examination, hemogram, biochemistry, 
chest skiagram, and computed tomography (whenever possible) were 
done. Chemotherapy was administered on an outpatient basis consist-
ing of irinotecan 70mg/m2, and cisplatin (60 mg/m2) with proper hydra-
tion and anti-emetics every 28 days. 
Result: There were 197 histogically proven patients. 92 had small cell 
histology and 107 had non small lung cancer. 37 are still receiving 
chemotherapy. Only those who completed three or more cycles of che-
motherapy were included for the data analysis. Thus data was analyzed 
for 65 small cell and 95 non-small types. There were 43 extensive and 
22 limited stage small cell lung cancers. There were 130 males (35 to 
70 years; 30 females (age 45-65). The performance status ranged from 
70 to 100 (Kornofsky scale). 66 patients received local radiotherapy of 
20 to 50Gy. 116 patients completed 5 cycles of and 26 completed four 
cycles. The remaining received three cycles of chemotherapy at the 
time of data analysis. Complete response was observed in 19 (11.8%) 
and partial in 36(22.5%). Lesions remained stable ranging from 8 
weeks to 354 weeks (median of 29weeks; for small cell lung cancer - 
34 weeks and non-small cell lung cancer- 28weeks) before progression. 
At the time of data analysis the median survival has been 39+ weeks 
for those who completed ﬁve cycles. For others it has been 27+ weeks 
and they are still under follow up. 93 patients (58.1%) are surviving be-
yond 6 months and 27 patients (16.9%) are alive beyond one year and 
13 patients (8.1%) are still alive after 2 years. 52 patients gained weight 
during therapy with the mean increase of 4.2kg and 43 lost weight with 
a mean of 2.4 kg. Performance status improved in 68 and deteriorated 
in 33; in the remaining patients it was static. Side effects were minimal 
(alopecia, nausea, vomiting, diarrhea, skin changes and neuropathy) 
and not serious. 
Discussion: Irinotecan and cisplatin regimen is effective and well toler-
ated in patients with new, relapsed or refractory SCLC and NSCLC 
(Hong et al 2006; Jeong et al 2006; Hino et al 2006). A four-arm 
co-operative study reported that this combination has similar efﬁcacy 
compared to three other commonly used regimens (Ohe et al 2006). 
The problem of chemotherapy in developing countries is of afford-
ability of newer drugs. The cost of the present regimen is less than US$ 
100. Thus those who wish to take the advantage of chemotherapy, but 
could not afford high cost of therapy with taxanes/gemcitabine, irinote-
can and cisplatin should be offered to them for improved survival. 
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Background: Only a minority of elderly pts receives palliative 
chemotherapy (CT) for advanced NSCLC although they may beneﬁt 
from treatment. Concerns exist with regard to toxicity, especially when 
platinum-based CT is administered. Single agent CT is considered 
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standard treatment for this age group. Several recent studies suggest 
superiority of combination CT, but little is known about QoL during 
CT. Also better assessments are needed to select elderly pts suitable for 
combination CT. The aim of this study was to investigate the effect of 
both platinum-based regimens on changes in QoL and the tolerability 
of these treatments in elderly NSCLC pts.
Methods: Eligible were pts ≥ 70 years with advanced NSCLC. They 
received carboplatin (AUC 5 day 1)-gemcitabine (1250 mg/m2 days 1 
and 8) or carboplatin (AUC 5 day 1)-paclitaxel (175 mg/m2 day 1), q 
3 weeks, for a maximum of 4 cycles. Darbepoetin was started if Hb < 
11 g/dL. Primary endpoint was the change in global QoL from baseline 
compared with week 18, using the EORTC QLQ-C30. Among the sec-
ondary endpoints were toxicity, response rate and survival. In addition, 
the value of a comprehensive geriatric assessment (CGA) was used.
Results: 182 pts were randomized. At the time of this analysis informa-
tion was available on 168 pts. Mean age was 75 yrs (range 70-85). PS 
= 0 in 30%, 1 in 57% and 2 in 13%. 64% of pts completed all 4 cycles, 
10% stopped treatment prematurely due to toxicity, 13% due to PD. 
Toxicity related dose-reductions occurred in 28 and 8% of pts and 
dose-delays in 15 and 3% of pts in the CG and CP arm, respectively. 
Overall, grade III/IV toxicity occurred in 65% of pts (75% in CG arm, 
56% in CP arm), toxicity related SAEs in 17% (20% in CG arm, 15% 
in CP arm), and 36% experienced ≥ grade 2 neurological toxicity (30% 
CG arm, 43% CP arm). Response rates were 28% in the CG arm vs 
20% in the CP arm. Median survival and progression-free survival were 
7.7 and 4.7 months for the CG arm and 6.6 and 4.4 months for the CP 
arm, respectively. 56 % of pts in the CG arm and 49% in the CP arm 
completed both the QoL questionnaires at baseline and after 18 weeks. 
Mean global QoL score at baseline did not differ between both arms 
(66% for GC and CP). After 18 weeks the mean QoL score for the CG 
arm had decreased by 2% and for the CP arm by 8% (NS). Further-
more, changes in Qol scores over the period of 18 weeks did not differ 
signiﬁcantly between both treatment arms. For experiencing grade 
III/IV toxicity related SAEs, neurological toxicities and for ﬁnishing all 
cycles, the use of a CGA was of predictive value.
Conclusions: In elderly patients with advanced NSCLC differences in 
treatment-related toxicity from gemcitabine and paclitaxel administered 
with carboplatin have no differential inﬂuence on QoL. Response and 
survival rates are similar for both groups. 
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Background: The combination of docetaxel and cisplatin is an ef-
fective ﬁrst-line chemotherapy for advanced NSCLC. However, the 
recommended three-weekly schedule is frequently associated with 
neutropenia and neutropenic infections. Moreover, the relatively long 
hydration required with cisplatin given every three weeks makes outpa-
tient treatment more difﬁcult. We assessed the efﬁcacy and tolerability 
of weekly docetaxel-cisplatin, which may be better tolerated than the 
standard regimen.
Methods: Patients (pts) with histologically conﬁrmed stage UICC IIIB 
(malignant effusion) or IV NSCLC received docetaxel (35 mg/m2, 30 
min. infusion) and cisplatin (25 mg/m2, 30-min. infusion) on days 1, 8, 
and 15, every 4 weeks for 4-6 cycles. Pts received ondansetron 8 mg iv 
and dexamethasone 8 mg iv preceding every day of chemotherapy and 
oral dexamethasone 2 x 4 mg daily from the day before until the day 
after chemotherapy. NK1-antagonists were given at the investigator’s 
discretion. Most pts were treated in an outpatient department. Safety 
was assessed using CTCAE v3.0. The primary endpoint was response 
rate (RECIST).
Results: 45 pts were included; efﬁcacy and tolerability data were avail-
able for 43 pts. 12/45 pts achieved an objective response (11 partial; 
1 complete; ITT response rate 27%). Median time to progression was 
3.9 months. Pts received a median of 3 full cycles. 4 pts (9%) required 
dose reductions. No cases of neutropenic fever/infections or grade 2-4 
thrombocytopenia were observed. One pt (2%) experienced grade 3/4 
nausea/vomiting. 5 pts died during therapy for reasons not unequivo-
cally attributable to tumor progression (bacterial meningitis with nor-
mal neutrophil counts [n=1], pneumonia with normal neutrophil counts 
[n=1], pulmonary arterial embolism [n=1], unknown [n=2]).
Conclusions: Weekly docetaxel-cisplatin was well tolerated. The 
schedule can be safely administered with relatively low hydration vol-
umes in an outpatient setting. Survival data will be presented.
P2-241 NSCLC: Cytotoxic Chemotherapy Posters, Tue, Sept 4 
A retrospective study of the role of chemotherapy in non-small 
cell lung cancer (nsclc) patients with brain metastases treated in 
Alberta, Canada from 2000-2004
Sangha, Randeep S.1 Chow, Laura Q.2 Trotter, Theresa3 Butts, Charles 
A.1 Hao, Desiree3 
1 Cross Cancer Institute, Edmonton, AB, Canada 2 Ottawa Regional 
Cancer Centre, Ottawa, ON, Canada 3 Tom Baker Cancer Centre, 
Calgary, AB, Canada 
Metastatic NSCLC clinical trials evaluating the role of palliative che-
motherapy often underrepresent or exclude patients with brain metas-
tases. The prognosis for this subgroup of patients remains poor and the 
advantage of chemotherapy, after deﬁnitive whole brain radiotherapy 
(WBRT), remains unclear. A retrospective chart review of NSCLC pa-
tients presenting with synchronous brain metastases in Alberta, Canada 
from 2000-2004 was undertaken to examine the possible beneﬁts of 
chemotherapy following WBRT. 497 chemonaive NSCLC patients with 
brain metastases received brain radiotherapy from 2000-2004, but only 
30 patients (6%) received subsequent chemotherapy. Of the 30 patients, 
the median age was 54 years (range 29 to 69 years), 40% were male, 
87% had an ECOG performance status ≤ 2 and 60% had adenocarci-
noma subtype of NSCLC. The treatment of the brain metastases, prior 
to chemotherapy, consisted primarily of WBRT (62% of patients irradi-
ated with 30 Gy in 10 fractions; 38% patients irradiated with 20 Gy in 
5 fractions), whereas only one patient underwent stereotactic radiosur-
gery. An intracranial response or stable disease was observed in 66% 
of patients. When treated with chemotherapy after brain radiotherapy, 
97% received a platinum-based doublet for a median of 4 cycles (range 
1-6). The response rate to ﬁrst-line chemotherapy was 30%, and 10 
